L
L. Calabrese
Researcher at Cleveland Clinic
Publications - 18
Citations - 711
L. Calabrese is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Internal medicine & Immunology. The author has an hindex of 7, co-authored 15 publications receiving 656 citations.
Papers
More filters
Journal ArticleDOI
Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection
TL;DR: Given the high prevalence of chronic viral infections in patients who are candidates for anti-TNF therapy and the potential for these agents in the treatment of Chronic viral illness, additional studies are urgently needed to assess the risks and benefits of such therapy in these populations.
EULAR points to consider in the development of classifi cation and diagnostic criteria in systemic vasculitis
Neil Basu,Richard Watts,Ingeborg M. Bajema,Bo Baslund,Thorsten A. Bley,Paul A. Brogan,L. Calabrese,Maria C. Cid,Jan Willem Cohen-Tervaert,David Jayne,Cees G. M. Kallenberg,Xavier Puéchal,Niels Rasmussen,Alan D. Salama,Carlo Salvarani,Caroline O.S. Savage,David G. I. Scott,V. Tesar,Allan Wiik +18 more
TL;DR: Limitations in current classification criteria and definitions for vasculitis have been identified and suggestions provided for improvement and it is proposed that, in combination with the updated evidence, these should form the basis of future attempts to develop and validate revised criteria and definition of vasulitis.
Journal ArticleDOI
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis
Neil Basu,Richard A. Watts,Ingeborg M. Bajema,Bo Baslund,Thorsten A. Bley,Maarten Boers,Paul A. Brogan,L. Calabrese,Maria C. Cid,Jan Willem Cohen-Tervaert,Luis Felipe Flores-Suárez,Shouichi Fujimoto,Kirsten de Groot,Loïc Guillevin,Gulen Hatemi,Thomas H. Hauser,David Jayne,Charles Jennette,Cees G. M. Kallenberg,Shigeto Kobayashi,Mark A. Little,Alfred Mahr,John McLaren,Peter A. Merkel,Seza Ozen,Xavier Puéchal,Niels Rasmussen,Alan D. Salama,Carlo Salvarani,Caroline O. S. Savage,David G. I. Scott,Mårten Segelmark,Ulrich Specks,C. Sunderkoetter,Kazuo Suzuki,Vladimir Tesar,Allan Wiik,Hasan Yazici,Raashid Luqmani +38 more
TL;DR: In this article, a systematic literature review was undertaken looking to address these deficiencies and produce 'points to consider' in accordance with standardised European League Against Rheumatism (EULAR) operating procedures.
Journal ArticleDOI
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance
Kevin L. Winthrop,Shannon A. Novosad,John W. Baddley,L. Calabrese,Tom Chiller,Philip M. Polgreen,F Bartalesi,Marc Lipman,Xavier Mariette,Olivier Lortholary,Michael E. Weinblatt,Michael S. Saag,Josef S Smolen +12 more
TL;DR: The consensus group developed a working definition for OIs as ‘indicator’ infections, defined as specific pathogens or presentations of pathogens that ’indicate’ the likelihood of an alteration in host immunity in the setting of biologic therapy.
Journal ArticleDOI
Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials
Vivian P. Bykerk,John J. Cush,K. Winthrop,L. Calabrese,Olivier Lortholary,M. de Longueville,R. van Vollenhoven,Xavier Mariette +7 more
TL;DR: While SIE rates were higher for CZP than for placebo in RCT, the rate decreased with continued exposure to CZp, consistent with data previously reported for CzP and other tumour necrosis factor inhibitors.